Health Care & Life Sciences » Biotechnology | Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. | Ownership

Companies that own Sunesis Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Eventide Asset Management LLC
2,265,455
6.27%
0
0.19%
06/30/2018
Balyasny Asset Management LP
2,200,000
6.09%
0
0.02%
06/30/2018
Tavistock Life Sciences Co. (Investment Management)
2,125,000
5.88%
0
0.32%
06/30/2018
BVF Partners LP
1,684,636
4.66%
0
0.25%
06/30/2018
Palo Alto Investors LP
1,162,473
3.22%
0
0.1%
06/30/2018
The Vanguard Group, Inc.
1,112,698
3.08%
-47,303
0%
06/30/2018
Baker Bros. Advisors LP
556,665
1.54%
0
0.01%
06/30/2018
Sabby Capital LLC
512,036
1.42%
512,036
0.55%
06/30/2018
Rhenman & Partners Asset Management AB
427,642
1.18%
-22,458
0.07%
06/30/2018
DAFNA Capital Management LLC
373,702
1.03%
0
0.32%
06/30/2018

About Sunesis Pharmaceuticals

View Profile
Address
395 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.sunesis.com
Updated 07/08/2019
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.